Overview

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

Status:
Completed
Trial end date:
2018-06-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of immunosuppression withdrawal (ISW) in pediatric liver transplant (tx) recipients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Immune Tolerance Network (ITN)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)